Andrzej Bożek, Agnieszka Bogacz-Piaseczyńska, Martyna Miodońska, Dominika Sadowska
{"title":"过敏原免疫治疗老年变应性鼻炎患者HDM的远期疗效。","authors":"Andrzej Bożek, Agnieszka Bogacz-Piaseczyńska, Martyna Miodońska, Dominika Sadowska","doi":"10.5114/ada.2023.129942","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Allergen immunotherapy (AIT) is an effective therapy for allergic rhinitis and may have long-term benefits. However, these benefits have not been strictly defined for older people.</p><p><strong>Aim: </strong>The evaluation of the effectiveness of AIT in patients over 60 with allergic rhinitis and house dust mites (HDM) allergy over a period of 7 years was performed.</p><p><strong>Material and methods: </strong>Patients after three years of HDM-AIT were observed to assess the sustained clinical effect of treatment. The average adjusted symptom score (AAdSS) and sIgG4 were monitored for 7 years after sublingual (SLIT) and injection AIT (SCIT).</p><p><strong>Results: </strong>After 3 years of HDM-AIT, a significant clinical effect was observed in the group after SLIT and SCIT based on AAdSS compared to the baseline and the placebo group (<i>p</i> < 0.05). After 7 years of follow-up, there was a sustained trend of decrease in clinical symptoms in desensitized patients relative to placebo. Serum sIgG4 was constantly present in all desensitized patients.</p><p><strong>Conclusions: </strong>AIT may be beneficial for treating seniors with allergic rhinitis and allergies to house dust mites.</p>","PeriodicalId":7212,"journal":{"name":"Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646711/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis.\",\"authors\":\"Andrzej Bożek, Agnieszka Bogacz-Piaseczyńska, Martyna Miodońska, Dominika Sadowska\",\"doi\":\"10.5114/ada.2023.129942\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Allergen immunotherapy (AIT) is an effective therapy for allergic rhinitis and may have long-term benefits. However, these benefits have not been strictly defined for older people.</p><p><strong>Aim: </strong>The evaluation of the effectiveness of AIT in patients over 60 with allergic rhinitis and house dust mites (HDM) allergy over a period of 7 years was performed.</p><p><strong>Material and methods: </strong>Patients after three years of HDM-AIT were observed to assess the sustained clinical effect of treatment. The average adjusted symptom score (AAdSS) and sIgG4 were monitored for 7 years after sublingual (SLIT) and injection AIT (SCIT).</p><p><strong>Results: </strong>After 3 years of HDM-AIT, a significant clinical effect was observed in the group after SLIT and SCIT based on AAdSS compared to the baseline and the placebo group (<i>p</i> < 0.05). After 7 years of follow-up, there was a sustained trend of decrease in clinical symptoms in desensitized patients relative to placebo. Serum sIgG4 was constantly present in all desensitized patients.</p><p><strong>Conclusions: </strong>AIT may be beneficial for treating seniors with allergic rhinitis and allergies to house dust mites.</p>\",\"PeriodicalId\":7212,\"journal\":{\"name\":\"Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646711/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/ada.2023.129942\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/ada.2023.129942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis.
Introduction: Allergen immunotherapy (AIT) is an effective therapy for allergic rhinitis and may have long-term benefits. However, these benefits have not been strictly defined for older people.
Aim: The evaluation of the effectiveness of AIT in patients over 60 with allergic rhinitis and house dust mites (HDM) allergy over a period of 7 years was performed.
Material and methods: Patients after three years of HDM-AIT were observed to assess the sustained clinical effect of treatment. The average adjusted symptom score (AAdSS) and sIgG4 were monitored for 7 years after sublingual (SLIT) and injection AIT (SCIT).
Results: After 3 years of HDM-AIT, a significant clinical effect was observed in the group after SLIT and SCIT based on AAdSS compared to the baseline and the placebo group (p < 0.05). After 7 years of follow-up, there was a sustained trend of decrease in clinical symptoms in desensitized patients relative to placebo. Serum sIgG4 was constantly present in all desensitized patients.
Conclusions: AIT may be beneficial for treating seniors with allergic rhinitis and allergies to house dust mites.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
